Forbes January 19, 2025
As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week her agency published a second report in six months critical of the pharmacy benefit manager industry. Specifically, the FTC accused PBMs of marking up the prices of specialty generic medicines, often far exceeding their acquisition costs, and then steering reimbursement towards their affiliated pharmacies. Khan stated that the practice contributes to rising pharmaceutical costs and higher out-of-pocket costs for patients. Furthermore, President-elect Trump recently reiterated his criticism of PBMs, calling them “rich as hell” and accused the intermediaries of being responsible for raising prescription drug prices. However, failure to include pharmaceutical pricing reforms that involve PBMs in the end-of-year continuing resolution, despite bipartisan support, may be...
Today's Sponsors
Today's Sponsor